Phibro Animal Health Corporation (PAHC)
USD 17.2
(0.94%)
USD 17.2
(0.94%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 725.54 Million USD | 5.32% |
| 2023 | 688.88 Million USD | 2.93% |
| 2022 | 669.25 Million USD | 11.03% |
| 2021 | 602.79 Million USD | 1.16% |
| 2020 | 595.89 Million USD | 16.69% |
| 2019 | 510.65 Million USD | 4.92% |
| 2018 | 486.72 Million USD | 3.07% |
| 2017 | 472.24 Million USD | -9.17% |
| 2016 | 519.89 Million USD | 12.12% |
| 2015 | 463.69 Million USD | 1.43% |
| 2014 | 457.17 Million USD | -15.82% |
| 2013 | 543.08 Million USD | 2.64% |
| 2012 | 529.13 Million USD | 0.0% |
| 2007 | 359.9 Million USD | 8.4% |
| 2006 | 332 Million USD | 11.41% |
| 2005 | 298 Million USD | -2.36% |
| 2004 | 305.2 Million USD | -14.96% |
| 2003 | 358.9 Million USD | 0.36% |
| 2002 | 357.6 Million USD | 9.49% |
| 2001 | 326.6 Million USD | 44.0% |
| 2000 | 226.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 701.9 Million USD | 1.51% |
| 2024 FY | 725.54 Million USD | 5.32% |
| 2024 Q3 | 708.94 Million USD | 1.0% |
| 2024 Q4 | 725.54 Million USD | 2.34% |
| 2024 Q1 | 691.45 Million USD | 0.37% |
| 2023 Q3 | 693.1 Million USD | -0.05% |
| 2023 Q1 | 685.62 Million USD | 2.45% |
| 2023 FY | 688.88 Million USD | 2.93% |
| 2023 Q4 | 688.88 Million USD | -0.61% |
| 2023 Q2 | 693.46 Million USD | 1.14% |
| 2022 FY | 669.25 Million USD | 11.03% |
| 2022 Q3 | 649.23 Million USD | 6.49% |
| 2022 Q4 | 669.25 Million USD | 3.08% |
| 2022 Q1 | 602.73 Million USD | -0.01% |
| 2022 Q2 | 609.66 Million USD | 1.15% |
| 2021 Q3 | 589.09 Million USD | -0.21% |
| 2021 Q4 | 602.79 Million USD | 2.33% |
| 2021 Q2 | 590.32 Million USD | -1.14% |
| 2021 FY | 602.79 Million USD | 1.16% |
| 2021 Q1 | 597.14 Million USD | 0.21% |
| 2020 FY | 595.89 Million USD | 16.69% |
| 2020 Q1 | 588.54 Million USD | 15.25% |
| 2020 Q3 | 580.7 Million USD | 1.72% |
| 2020 Q4 | 595.89 Million USD | 2.62% |
| 2020 Q2 | 570.9 Million USD | -3.0% |
| 2019 Q2 | 492.06 Million USD | 1.16% |
| 2019 Q3 | 492.7 Million USD | 0.13% |
| 2019 Q4 | 510.65 Million USD | 3.64% |
| 2019 FY | 510.65 Million USD | 4.92% |
| 2019 Q1 | 486.41 Million USD | -0.06% |
| 2018 Q1 | 501.63 Million USD | 6.22% |
| 2018 Q3 | 485.29 Million USD | -1.92% |
| 2018 Q4 | 486.72 Million USD | 0.29% |
| 2018 FY | 486.72 Million USD | 3.07% |
| 2018 Q2 | 494.8 Million USD | -1.36% |
| 2017 Q3 | 462.86 Million USD | -3.5% |
| 2017 Q4 | 472.24 Million USD | 2.02% |
| 2017 FY | 472.24 Million USD | -9.17% |
| 2017 Q1 | 495.8 Million USD | -4.63% |
| 2017 Q2 | 479.67 Million USD | -3.25% |
| 2016 Q4 | 519.89 Million USD | 1.51% |
| 2016 Q3 | 512.18 Million USD | 9.4% |
| 2016 Q1 | 470.87 Million USD | 1.55% |
| 2016 Q2 | 468.18 Million USD | -0.57% |
| 2016 FY | 519.89 Million USD | 12.12% |
| 2015 Q3 | 449.25 Million USD | 1.73% |
| 2015 FY | 463.69 Million USD | 1.43% |
| 2015 Q4 | 463.69 Million USD | 3.21% |
| 2015 Q2 | 441.63 Million USD | -1.69% |
| 2015 Q1 | 449.21 Million USD | -1.74% |
| 2014 Q4 | 457.17 Million USD | -17.18% |
| 2014 Q1 | 546.1 Million USD | 0.56% |
| 2014 FY | 457.17 Million USD | -15.82% |
| 2014 Q2 | 544.35 Million USD | -0.32% |
| 2014 Q3 | 552 Million USD | 1.4% |
| 2013 Q4 | 543.08 Million USD | 0.0% |
| 2013 FY | 543.08 Million USD | 2.64% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 529.13 Million USD | 0.0% |
| 2007 FY | 359.9 Million USD | 8.4% |
| 2006 Q3 | 292.7 Million USD | 0.48% |
| 2006 FY | 332 Million USD | 11.41% |
| 2006 Q1 | 294.5 Million USD | -1.17% |
| 2006 Q2 | 291.3 Million USD | -1.09% |
| 2005 Q2 | 325.1 Million USD | 6.56% |
| 2005 Q1 | 305.1 Million USD | -0.03% |
| 2005 FY | 298 Million USD | -2.36% |
| 2005 Q4 | 298 Million USD | 0.57% |
| 2005 Q3 | 296.3 Million USD | -8.86% |
| 2004 Q1 | 361 Million USD | 0.59% |
| 2004 Q4 | 305.2 Million USD | 1.36% |
| 2004 Q3 | 301.1 Million USD | 1.04% |
| 2004 FY | 305.2 Million USD | -14.96% |
| 2004 Q2 | 298 Million USD | -17.45% |
| 2003 Q2 | 364.4 Million USD | 3.32% |
| 2003 Q1 | 352.7 Million USD | 0.0% |
| 2003 FY | 358.9 Million USD | 0.36% |
| 2003 Q4 | 358.9 Million USD | 0.48% |
| 2003 Q3 | 357.2 Million USD | -1.98% |
| 2002 FY | 357.6 Million USD | 9.49% |
| 2001 FY | 326.6 Million USD | 44.0% |
| 2000 FY | 226.8 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -342.661% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 23.456% |
| Journey Medical Corporation | 56.49 Million USD | -1184.17% |
| Dynavax Technologies Corporation | 375.02 Million USD | -93.466% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -9.799% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -430.093% |
| Pacira BioSciences, Inc. | 704.25 Million USD | -3.023% |
| PainReform Ltd. | 2.69 Million USD | -26861.836% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -3303.785% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -11717.431% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -11717.431% |
| SCYNEXIS, Inc. | 55.45 Million USD | -1208.463% |
| Silver Spike Investment Corp. | 3 Million USD | -24005.772% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -7789.243% |
| Alpha Teknova, Inc. | 38.55 Million USD | -1782.034% |
| Alvotech | 1.88 Billion USD | 61.46% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | -53.823% |
| Bright Green Corporation | 6.43 Million USD | -11169.517% |
| Embecta Corp. | 2.03 Billion USD | 64.366% |
| Safety Shot Inc | 3.89 Million USD | -18541.696% |
| Procaps Group, S.A. | 462.06 Million USD | -57.022% |
| Cosmos Health Inc. | 30.25 Million USD | -2298.289% |
| Theratechnologies Inc. | 98.63 Million USD | -635.554% |
| Harrow Health, Inc. | 241.75 Million USD | -200.117% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -8186.238% |
| Biofrontera Inc. | 23.13 Million USD | -3035.585% |
| DURECT Corporation | 30.4 Million USD | -2286.184% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -48.841% |
| Cronos Group Inc. | 43.73 Million USD | -1558.912% |
| OptiNose, Inc. | 194.33 Million USD | -273.347% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 11.234% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -1397.663% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -3358.57% |
| Organogenesis Holdings Inc. | 181.36 Million USD | -300.052% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -19134.285% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -1281.56% |
| Radius Health, Inc. | 804.29 Million USD | 9.791% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -5175.015% |
| ProPhase Labs, Inc. | 42.54 Million USD | -1605.394% |
| Procaps Group S.A. | 462.06 Million USD | -57.022% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -5074.319% |
| Viatris Inc. | 27.21 Billion USD | 97.334% |
| Rockwell Medical, Inc. | 30.88 Million USD | -2249.404% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -702.778% |
| SIGA Technologies, Inc. | 57.97 Million USD | -1151.426% |
| Tilray Brands, Inc. | 892.11 Million USD | 18.672% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | -230.092% |
| Shineco, Inc. | 47.6 Million USD | -1424.196% |
| PetIQ, Inc. | 645.22 Million USD | -12.448% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -330425.438% |
| Incannex Healthcare Limited | 5.83 Million USD | -12344.991% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 28.826% |
| Alimera Sciences, Inc. | 107.35 Million USD | -575.842% |
| Assertio Holdings, Inc. | 148.41 Million USD | -388.858% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -38167.742% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -10226.544% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -8445.319% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | -318.453% |
| Hempacco Co., Inc. | 18.82 Million USD | -3754.677% |
| Talphera, Inc. | 6.29 Million USD | -11434.865% |
| Alvotech | 1.88 Billion USD | 61.46% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -320.361% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 13.135% |
| Currenc Group, Inc. | 177.67 Million USD | -308.352% |
| Kamada Ltd. | 109.96 Million USD | -559.775% |
| Indivior PLC | 1.95 Billion USD | 62.816% |
| Evoke Pharma, Inc. | 9.64 Million USD | -7420.074% |
| Flora Growth Corp. | 17.22 Million USD | -4112.885% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -8445.319% |
| Evolus, Inc. | 209.68 Million USD | -246.012% |
| HUTCHMED (China) Limited | 536.38 Million USD | -35.265% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 16.938% |
| Akanda Corp. | 12.66 Million USD | -5626.968% |